<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02595060</url>
  </required_header>
  <id_info>
    <org_study_id>MOL-ARDS-002</org_study_id>
    <nct_id>NCT02595060</nct_id>
  </id_info>
  <brief_title>Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Inhalation to Improve Host Defense and Pulmonary Barrier Restoration</brief_title>
  <acronym>GI-HOPE</acronym>
  <official_title>GM-CSF Inhalation to Improve Host Defense and Pulmonary Barrier Restoration (GI-HOPE). A Randomized, Double-blind, Parallel Group, Multicenter, Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Giessen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Giessen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial evaluates efficacy and safety of inhaled molgramostim (rhGM-CSF) in 45 patients
      with pneumonia associated acute respiratory distress syndrome (ARDS). A third of the patients
      will receive 150 mcg inhaled molgramostim, another third 450 mcg and the remaining third will
      receive inhaled placebo for 3 days. The patients will be followed for 28 days.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GI-HOPE score representing changes at Day 4/5 with respect to Baseline (Day -1)</measure>
    <time_frame>baseline and Day 4/5</time_frame>
    <description>The GI-HOPE score assesses change in bronchoalveolar lavage fluid (BALF) mononuclear phagocyte activation/polarization by flow cytometry (mean fluorescence intensities of parameters CD80, CD86, CD206, HLA-DR) with respect to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Adverse Events (AE), Serious AEs and Adverse Drug Reactions</measure>
    <time_frame>baseline to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygenation</measure>
    <time_frame>Baseline to Day 11</time_frame>
    <description>PaO2/FiO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Physiology and Chronic Health Evaluation (APACHE)</measure>
    <time_frame>Baseline to Day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment (SOFA)</measure>
    <time_frame>Baseline to Day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extravascular Lung Water Index</measure>
    <time_frame>Baseline to Day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive Protein</measure>
    <time_frame>Baseline to Day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days on vasoactive drugs</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum GM-CSF</measure>
    <time_frame>Baseline, Days 1-4</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>ARDS</condition>
  <arm_group>
    <arm_group_label>150 mcg inhaled molgramostim</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily inhaled molgramostim (rhGM-CSF) for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>450 mcg inhaled molgramostim</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily inhaled molgramostim (rhGM-CSF) for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>inhaled placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>once daily inhaled placebo for 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inhaled molgramostim (rhGM-CSF)</intervention_name>
    <arm_group_label>150 mcg inhaled molgramostim</arm_group_label>
    <arm_group_label>450 mcg inhaled molgramostim</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inhaled placebo</intervention_name>
    <description>formulated as the active substance without molgramostim</description>
    <arm_group_label>inhaled placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent form by the patient or a legal representative according to
             local regulations

          2. Man or woman 18 to 75 years of age, inclusive

          3. Women who have been post-menopausal for more than 1 year or women of childbearing
             potential period using a highly efficient method of contraception (i.e. a method with
             less than 1% failure rate such as combined hormonal contraception, progesterone-only
             hormonal contraception, intrauterine device, intrauterine hormone-releasing system,
             bilateral tube occlusion, vasectomized partner, sexual abstinence) during dosing and
             hospitalisation. Women must have a negative serum or urine pregnancy test before the
             first dose of study medication and must not be lactating.

          4. Diagnosis of pneumonia-associated ARDS, where the underlying condition is
             Community-Acquired Pneumonia (CAP) or Hospital-Acquired Pneumonia (HAP) in patients
             not on invasive ventilation upon diagnosis of HAP.

          5. Diagnosis of ARDS according to the Berlin ARDS definition.

          6. Requirement for positive pressure ventilation (non-invasive or via endotracheal tube)
             for more than 72 hours in total with inspiratory oxygen concentration (FiO2) ≥ 50% (or
             less when on additional ECMO therapy) not longer than 14 days

        Exclusion Criteria:

          1. Receiving vasopressors of &gt;100 µg/min

          2. History of liver cirrhosis Child Pugh C, chronic hemodialysis (before severe
             pneumonia/ARDS), lung cancer

          3. Malignancy with expected survival time of less than 6 months

          4. History of or listing for lung transplantation

          5. Highly immunosuppressive therapy or anti-malignant combination chemotherapy within 3
             weeks prior to first dose of study drug

          6. Any anti-malignant chemotherapy within 24 hours prior to first dose of study drug

          7. AIDS or known history of HIV infection

          8. Pregnancy

          9. Autoimmune thrombocytopenia, myelodysplastic syndromes with &gt; 20% marrow blast cells

         10. History or presence of hypersensitivity or idiosyncratic reaction to molgramostim or
             to related compounds (i.e., Growgen®, Leucomax®, Leukine™, Topleucon™)

         11. Participation in another clinical trial within 90 days prior to the first dose of
             study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanne Herold, Prof.Dr.med.,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universities of Giessen and Marburg Lung Centers, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susanne Herold, Prof.Dr.med.,PhD</last_name>
    <email>susanne.herold@innere.med.uni-giessen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katarzyna Piskulak, Dr.</last_name>
    <email>katarzyna.piskulak@KKS.uni-marburg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt, Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kai Zacharowski, Prof. Dr. Dr., MD</last_name>
    </contact>
    <investigator>
      <last_name>Kai Zacharowski, Prof. Dr. Dr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universities of Marburg and Giessen Lung Center</name>
      <address>
        <city>Giessen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Herold, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf, Klinik für Intensivmedizin</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Kluge, MD, Prof. Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Stefan Kluge, MD, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Klinik für Pneumologie</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Welte, Prof. Dr., MD</last_name>
    </contact>
    <investigator>
      <last_name>Tobias Welte, Prof. Dr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena, Klinik für Anästhesiologie und Intensivmedizin</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Bauer, MD, Prof. Dr</last_name>
    </contact>
    <investigator>
      <last_name>Michael Bauer, MD, Prof. Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Marburg, Department of Anaesthesiology and Intensive Care Medicine</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hinnerk Wulf, MD, Prof. Dr</last_name>
    </contact>
    <investigator>
      <last_name>Hinnerk Wulf, MD, Prof. Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Herold S, Hoegner K, Vadász I, Gessler T, Wilhelm J, Mayer K, Morty RE, Walmrath HD, Seeger W, Lohmeyer J. Inhaled granulocyte/macrophage colony-stimulating factor as treatment of pneumonia-associated acute respiratory distress syndrome. Am J Respir Crit Care Med. 2014 Mar 1;189(5):609-11. doi: 10.1164/rccm.201311-2041LE.</citation>
    <PMID>24579839</PMID>
  </reference>
  <reference>
    <citation>Cakarova L, Marsh LM, Wilhelm J, Mayer K, Grimminger F, Seeger W, Lohmeyer J, Herold S. Macrophage tumor necrosis factor-alpha induces epithelial expression of granulocyte-macrophage colony-stimulating factor: impact on alveolar epithelial repair. Am J Respir Crit Care Med. 2009 Sep 15;180(6):521-32. doi: 10.1164/rccm.200812-1837OC. Epub 2009 Jul 9.</citation>
    <PMID>19590023</PMID>
  </reference>
  <reference>
    <citation>Unkel B, Hoegner K, Clausen BE, Lewe-Schlosser P, Bodner J, Gattenloehner S, Janßen H, Seeger W, Lohmeyer J, Herold S. Alveolar epithelial cells orchestrate DC function in murine viral pneumonia. J Clin Invest. 2012 Oct;122(10):3652-64. doi: 10.1172/JCI62139. Epub 2012 Sep 10.</citation>
    <PMID>22996662</PMID>
  </reference>
  <reference>
    <citation>Ballinger MN, Paine R 3rd, Serezani CH, Aronoff DM, Choi ES, Standiford TJ, Toews GB, Moore BB. Role of granulocyte macrophage colony-stimulating factor during gram-negative lung infection with Pseudomonas aeruginosa. Am J Respir Cell Mol Biol. 2006 Jun;34(6):766-74. Epub 2006 Feb 10.</citation>
    <PMID>16474098</PMID>
  </reference>
  <reference>
    <citation>Standiford LR, Standiford TJ, Newstead MJ, Zeng X, Ballinger MN, Kovach MA, Reka AK, Bhan U. TLR4-dependent GM-CSF protects against lung injury in Gram-negative bacterial pneumonia. Am J Physiol Lung Cell Mol Physiol. 2012 Mar 1;302(5):L447-54. doi: 10.1152/ajplung.00415.2010. Epub 2011 Dec 9.</citation>
    <PMID>22160309</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2015</study_first_submitted>
  <study_first_submitted_qc>November 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2015</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute lung injury, molgramostim, GM-CSF, pneumonia, barrier restoration</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Molgramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

